USX:CGIX - Cancer Genetics Inc. (USD 3.1) Cancer Genetics Inc.
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance

USD 3.1    -0.190 (-5.78%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


9 Apr 2020

Day Change: -0.190 (-5.78%)

52 Wk Range: 0.085 - 9.5

Day's Range: 3.0722 - 3.37

Last Volume: 26,094

Current Yield: 0%

Projected Yield: 0%

Open: USD 3.12

9 Apr 2020

Metric CGIX S.Median
Beta 1.76 0.84
VaR 1,278.79 25.23
E.Shortfall 1,278.79 45.03
Liquidity 30.08K 95.2K


9 Apr 2020

PE: -0.609

Market Cap: 6.2M

Price Over Book: 0.831

Price Over Sales: 0.22

Return On Assets: -49.1%

Return On Equity: -136.4%

Price Over NAV: [Friends Only]


CEO: Panna L. Sharma

Headquarters: RUTHERFORD

Employees: 150

Sector: Health Technology

Industry: Medical Specialties

Useful Links


Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.